Immunohistochemical expression of interleukin-4, -6, -8, and -12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma

Head and Neck

Volumn 31, Issue 11, 2009, Pages 1439-1446

  De Oliveira, Marcos Vinícius Macedo ^a   Fraga, Carlos Alberto De Carvalho ^a   Gomez, Ricardo Santiago ^b   Paula, Alfredo Maurício Batista D ^a  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Immunohistochemical; Inflammatory cells; Interleukins 4, 6, 8, and 12; Oral squamous cell carcinoma; Prognosis

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; FEMALE; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INVASIVE CARCINOMA; MALE; MOUTH CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FROZEN SECTIONS; HUMANS; INFLAMMATION; INTERLEUKINS; LEUKOCYTES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 70350343174     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21121     Document Type: Article

References (59)

1. Bagan JV, Scully C. Recent advances in Oral Oncology 2007: epidemiology, aetiopathogenesis, diagnosis and prognostication. Oral Oncol 2008;44:103-108.
2. Jefferies S, Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol 2001;37:115-126. (Pubitemid 32146656)
3. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncol 2000;36:404-413. (Pubitemid 30645974)
4. Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53:165-172. (Pubitemid 30603069)
5. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006;17:141-146.
6. Stein RC, Dalgleish AG. Immunomodulatory agents: the cytokines. Eur J Cancer A 1994;30:400-404.
7. Mann EA, Spiro JD, Chen LL, Kreutzer DL. Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 1992;164:567-573.
8. Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005;93:159-187.
9. Callard RE. Immunoregulation by interleukin-4 in man. Br J Haematol 1991;78:293-299.
10. Yssel H, Schneider P, Spits H. Production of IL4 by human T cells and regulation of differentiation of T-cell subsets by IL4. Res Immunol 1993;144:610-616. (Pubitemid 24009455)
11. Beppu M, Ikebe T, Shirasuna K. The inhibitory effects of immunosuppressive factors, dexamethasone and interleukin-4, on NF-kappaB-mediated protease production by oral cancer. Biochim Biophys Acta 2002;1586:11-22. (Pubitemid 34066612)
12. Herzberg F, Schoning M, Schirner M, Topp M, Thiel E, Kreuser ED. IL-4 and TNF-alpha induce changes in integrin expression and adhesive properties and decrease the lung-colonizing potential of HT-29 colon carcinoma cells. Clin Exp Metastasis 1996;14:165-175.
13. Morisaki T, Yuzuki DH, Lin RT, Foshag LJ, Morton DL, Hoon DS. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res 1992;52:6059-6065.
14. Volpert OV, Fong T, Koch AE, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188:1039-1046.
15. Myers JN, Yasumura S, Suminami Y, et al. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 1996;2:127-135. (Pubitemid 26042187)
16. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999;189:803-810. (Pubitemid 29189685)
17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20. (Pubitemid 37046923)
18. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593-597.
19. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005;65:10794-10800.
20. Wang YF, Chang SY, Tai SK, Li WY, Wang LS. Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head Neck 2002;24:850-858. (Pubitemid 34913256)
21. Yamaji H, Iizasa T, Koh E, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 2004;53:786-792. (Pubitemid 39149905)
22. Riedel F, Zaiss I, Herzog D, Gotte K, Naim R, Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005;25:2761-2765. (Pubitemid 41044658)
23. Nishino H, Miyata M, Kitamura K. The effect of interleukin-6 on enhancing the invasiveness of head and neck cancer cells in vitro. Eur Arch Otorhinolaryngol 1998;255:468-472. (Pubitemid 28510710)
24. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008-1015. (Pubitemid 34017290)
25. Ashizawa T, Okada R, Suzuki Y, et al. Study of interleukin-6 in the spread of colorectal cancer: the diagnostic significance of IL-6. Acta Med Okayama 2006;60:325-330. (Pubitemid 46142087)
26. Cohen RF, Contrino J, Spiro JD, Mann EA, Chen LL, Kreutzer DL. Interleukin-8 expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121:202-209.
27. Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 1999;109:687-693. (Pubitemid 29227910)
28. Strieter RM, Kunkel SL, Elner VM, et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 1992;141:1279-1284. (Pubitemid 23002612)
29. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 2004;91:1970-1976. (Pubitemid 40065527)
30. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 2003;22:765-771.
31. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151:1105-1113. (Pubitemid 27424320)
32. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158:735-743. (Pubitemid 32158635)
33. Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9:729-737. (Pubitemid 36182607)
34. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-168.
35. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-1452. (Pubitemid 28145262)
36. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-1621. (Pubitemid 29102489)
37. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-1230. (Pubitemid 23277355)
38. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993;14:335-338. (Pubitemid 23198164)
39. Ha SJ, Lee SB, Kim CM, Shin HS, Sung YC. Rapid recruitment of macrophages in interleukin-12-mediated tumour regression. Immunology 1998;95:156-163.
40. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000;60:1111-1116. (Pubitemid 30129553)
41. Brunda MJ, Luistro L, Rumennik L, et al. Interleukin-12: murine models of a potent antitumor agent. Ann NY Acad Sci 1996;795:266-274. (Pubitemid 27029575)
42. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002;20:1862-1869.
43. Sobin LH, Wittekind C. ID: TNM classification of malignant tumors, sixth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. 2002;80:1803-1804.
44. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.
45. Pindborg JJ, Hansen J. Histological examination of a reimplanted second incisor. (Netherland) Tandlaegebladet 1951;55:93-101.
46. Bryne M, Nielsen K, Koppang HS, Dabelsteen E. Reproducibility of two malignancy grading systems with reportedly prognostic value for oral cancer patients. J Oral Pathol Med 1991;20:369-372.
47. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 1992;166:375-381.
48. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180-186. (Pubitemid 40343106)
49. Woolgar JA. The national head and neck histopathology external quality assurance scheme: evolution, design, and analysis of 11 circulations from 1999 to 2005. J Clin Pathol 2006;59:482-488.
50. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004;131:573-576. (Pubitemid 39446277)
51. Lalla RV, Goralnick SJ, Tanzer ML, Kreutzer DL. Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells. Oral Oncol 2001;37:234-242.
52. Lalla RV, Tanzer ML, Kreutzer DL. Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells. Arch Oral Biol 2003;48:263-271.
53. Lalla RV, Spiro JD, Tanzer ML, Kreutzer DL. Association of fibrin and interleukin 8 in human oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:452-457. (Pubitemid 36877319)
54. Richards BL, Eisma RJ, Spiro JD, Lindquist RL, Kreutzer DL. Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg 1997;174:507-512. (Pubitemid 27486015)
55. Magnusson PU, Dimberg A, Mellberg S, Lukinius A, Claesson-Welsh L. FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin. Blood 2007;110:4214-4222.
56. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
57. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis. In Vivo 1998;12:27-34.
58. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res 2000;60:2632-2635. (Pubitemid 30318237)
59. Fujimoto J, Aoki I, Khatun S, Toyoki H, Tamaya T. Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Ann Oncol 2002;13:430-434. (Pubitemid 34705005)